Compare CLPT & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLPT | BWAY |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.6M | 451.2M |
| IPO Year | N/A | 2019 |
| Metric | CLPT | BWAY |
|---|---|---|
| Price | $13.27 | $22.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $26.50 | $26.50 |
| AVG Volume (30 Days) | ★ 749.7K | 126.1K |
| Earning Date | 02-25-2026 | 03-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 213.09 |
| EPS | N/A | ★ 0.13 |
| Revenue | $34,332,000.00 | ★ $49,094,000.00 |
| Revenue This Year | $18.93 | $330.76 |
| Revenue Next Year | $51.64 | $22.24 |
| P/E Ratio | ★ N/A | $73.20 |
| Revenue Growth | 12.83 | ★ 27.08 |
| 52 Week Low | $9.76 | $7.84 |
| 52 Week High | $30.10 | $25.65 |
| Indicator | CLPT | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 44.67 | 49.62 |
| Support Level | $12.77 | $22.97 |
| Resistance Level | $14.33 | $25.65 |
| Average True Range (ATR) | 0.94 | 1.37 |
| MACD | -0.11 | -0.37 |
| Stochastic Oscillator | 18.75 | 20.75 |
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, ClearPoint Disposables, ClearPoint Software, and ClearPoint Therapeutic Solutions.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.